Log In
Print
BCIQ
Print
Print this Print this
 

Actair, House dust mites sublingual immunotherapy tablet (S-524101)

  Manage Alerts
Collapse Summary General Information
Company Stallergenes S.A.
DescriptionSublingual desensitization tablet to house dust mite allergies
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationAllergy
Indication DetailsTreat house dust mite allergic rhinitis
Regulatory Designation Japan - Standard Review (Treat house dust mite allergic rhinitis)
Partner Shionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$31.0M

$59.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today